Augmentation of learning in schizophrenia by d-serine and auditory remediation is related to auditory and frontally-generated biomarkers: A randomized, double-blind, placebo-controlled study.
作者信息
Govani Viraj, Shastry Adithya M, Iosifescu Dan V, Govil Preetika, Mayer Megan R, Sobeih Tarek, Choo Tse-Hwei, Wall Melanie M, Sehatpour Pejman, Kantrowitz Joshua T
机构信息
New York State Psychiatric Institute, New York, NY, United States of America.
New York State Psychiatric Institute, New York, NY, United States of America; Columbia University, College of Physicians and Surgeons, New York, NY, United States of America.
出版信息
Schizophr Res. 2023 Oct;260:205-208. doi: 10.1016/j.schres.2023.08.027. Epub 2023 Sep 11.
Abstract
摘要
相似文献
1
Augmentation of learning in schizophrenia by d-serine and auditory remediation is related to auditory and frontally-generated biomarkers: A randomized, double-blind, placebo-controlled study.
Schizophr Res. 2023 Oct;260:205-208. doi: 10.1016/j.schres.2023.08.027. Epub 2023 Sep 11.
2
Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine.
Biol Psychiatry. 2023 Jul 15;94(2):164-173. doi: 10.1016/j.biopsych.2023.01.015. Epub 2023 Jan 28.
3
Augmentation of learning in schizophrenia by D-serine is related to auditory and frontally-generated biomarkers: A randomized, double-blind, placebo-controlled study.
Res Sq. 2023 May 19:rs.3.rs-2943290. doi: 10.21203/rs.3.rs-2943290/v1.
4
Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Arch Gen Psychiatry. 2005 Nov;62(11):1196-204. doi: 10.1001/archpsyc.62.11.1196.
5
Grant Report on d-Serine Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia .
J Psychiatr Brain Sci. 2020;5(4). Epub 2020 Aug 6.
6
Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
Schizophr Res. 2018 Jan;191:70-79. doi: 10.1016/j.schres.2017.02.027. Epub 2017 Mar 18.
7
Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function.
Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 Jul;3(7):581-590. doi: 10.1016/j.bpsc.2018.02.002. Epub 2018 Feb 22.
8
A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
J Clin Psychiatry. 2012 Jun;73(6):e728-34. doi: 10.4088/JCP.11m07031.
9
Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine.
Brain. 2016 Dec;139(Pt 12):3281-3295. doi: 10.1093/brain/aww262.
10
A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia.
Int J Neuropsychopharmacol. 2010 May;13(4):451-60. doi: 10.1017/S1461145709990939. Epub 2009 Nov 4.
引用本文的文献
1
The Less Things Change, the More They Remain the Same: Impaired Neural Plasticity as a Critical Target for Drug Development in Neuropsychiatry.
Adv Neurobiol. 2024;40:801-828. doi: 10.1007/978-3-031-69491-2_26.
2
Finding the Right Dose: NMDA Receptor-Modulating Treatments for Cognitive and Plasticity Deficits in Schizophrenia and the Role of Pharmacodynamic Target Engagement.
Biol Psychiatry. 2025 Jan 15;97(2):128-138. doi: 10.1016/j.biopsych.2024.08.019. Epub 2024 Aug 30.
Zotero 插件